<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 28 Apr 2021 07:25:28 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>糖尿病领域新王者：Tirzepatide</title><link>https://mp.weixin.qq.com/s/9kvGvLQPfmzR7PWdoMt40w</link><description></description><content:encoded><![CDATA[糖尿病领域新王者：Tirzepatide]]></content:encoded><pubDate>Wed, 28 Apr 2021 06:39:40 +0800</pubDate></item><item><title>信达生物PD-1一季度超7亿元，</title><link>https://mp.weixin.qq.com/s/rNDENZR-XEsgaHnH8oF9pQ</link><description></description><content:encoded><![CDATA[信达生物PD-1一季度超7亿元，]]></content:encoded><pubDate>Wed, 28 Apr 2021 06:39:40 +0800</pubDate></item><item><title>君实/礼来新冠中和抗体一季度销售额8.1亿美元</title><link>https://mp.weixin.qq.com/s/gCEgf4wbuadorYxmSAyvjQ</link><description></description><content:encoded><![CDATA[君实/礼来新冠中和抗体一季度销售额8.1亿美元]]></content:encoded><pubDate>Wed, 28 Apr 2021 06:39:40 +0800</pubDate></item><item><title>替雷利珠单抗：诺华年底前向FDA递交上市申请</title><link>https://mp.weixin.qq.com/s/X3LvaG4L3ks9A8n82Dyxag</link><description></description><content:encoded><![CDATA[替雷利珠单抗：诺华年底前向FDA递交上市申请]]></content:encoded><pubDate>Tue, 27 Apr 2021 22:32:39 +0800</pubDate></item><item><title>百奥泰申报TIGIT抗体，国内第4家</title><link>https://mp.weixin.qq.com/s/JWW7Of7T5cCHzig5OCvGzg</link><description></description><content:encoded><![CDATA[百奥泰申报TIGIT抗体，国内第4家]]></content:encoded><pubDate>Tue, 27 Apr 2021 22:32:39 +0800</pubDate></item><item><title>百利药业申报第3个四抗：PD-L1/CD3/4-1BB/ROR1</title><link>https://mp.weixin.qq.com/s/57QgNvRZlg9fjZfD3gYQPQ</link><description></description><content:encoded><![CDATA[百利药业申报第3个四抗：PD-L1/CD3/4-1BB/ROR1]]></content:encoded><pubDate>Tue, 27 Apr 2021 22:32:39 +0800</pubDate></item><item><title>贝达药业申报CTLA-4抗体</title><link>https://mp.weixin.qq.com/s/4FNo2pLqNUm0vGHrkhEfGQ</link><description></description><content:encoded><![CDATA[贝达药业申报CTLA-4抗体]]></content:encoded><pubDate>Tue, 27 Apr 2021 22:32:39 +0800</pubDate></item><item><title>康弘药业修正2020业绩：康柏西普14亿元支出计入损失</title><link>https://mp.weixin.qq.com/s/QCTa1QAPLTFfHqokdlWQ_A</link><description></description><content:encoded><![CDATA[康弘药业修正2020业绩：康柏西普14亿元支出计入损失]]></content:encoded><pubDate>Mon, 26 Apr 2021 07:19:01 +0800</pubDate></item><item><title>CAR-T：Linker长度至关重要</title><link>https://mp.weixin.qq.com/s/9Yh_63CAc7dAg1KFO_65zA</link><description></description><content:encoded><![CDATA[CAR-T：Linker长度至关重要]]></content:encoded><pubDate>Mon, 26 Apr 2021 07:19:01 +0800</pubDate></item><item><title>三叶草生物技术全梳理</title><link>https://mp.weixin.qq.com/s/9uGZvEV3SszevoHMGfK60A</link><description></description><content:encoded><![CDATA[三叶草生物技术全梳理]]></content:encoded><pubDate>Sun, 25 Apr 2021 21:30:31 +0800</pubDate></item><item><title>FDA批准CD19 ADC药物，瓴路药业拥有中国权益</title><link>https://mp.weixin.qq.com/s/TjDmw5kR0ET6NQkUVi1ciw</link><description></description><content:encoded><![CDATA[FDA批准CD19 ADC药物，瓴路药业拥有中国权益]]></content:encoded><pubDate>Sat, 24 Apr 2021 06:49:35 +0800</pubDate></item><item><title>柳叶刀：索马鲁肽与Amylin联用，减重效果翻倍</title><link>https://mp.weixin.qq.com/s/OCo5QPgKMCMZPhCztHayWQ</link><description></description><content:encoded><![CDATA[柳叶刀：索马鲁肽与Amylin联用，减重效果翻倍]]></content:encoded><pubDate>Sat, 24 Apr 2021 06:49:35 +0800</pubDate></item><item><title>FDA批准第4款PD-1抗体：葛兰素史克Dostarlimab，药明生物提供CMO服务</title><link>https://mp.weixin.qq.com/s/aWQ2CYp_Wsl7UXtIX7lt5w</link><description></description><content:encoded><![CDATA[FDA批准第4款PD-1抗体：葛兰素史克Dostarlimab，药明生物提供CMO服务]]></content:encoded><pubDate>Fri, 23 Apr 2021 12:18:33 +0800</pubDate></item><item><title>健艾仕新药申报临床：GEC-255</title><link>https://mp.weixin.qq.com/s/z8r-fkB9f022r5G8bO7ZxQ</link><description></description><content:encoded><![CDATA[健艾仕新药申报临床：GEC-255]]></content:encoded><pubDate>Fri, 23 Apr 2021 12:18:33 +0800</pubDate></item><item><title>国内第2款：维立志博申报PD-1/TGFβ双抗</title><link>https://mp.weixin.qq.com/s/_GNhQerSi79rYMZaz1s1bw</link><description></description><content:encoded><![CDATA[国内第2款：维立志博申报PD-1/TGFβ双抗]]></content:encoded><pubDate>Fri, 23 Apr 2021 12:18:33 +0800</pubDate></item><item><title>海普瑞申报卵巢癌抗体疫苗Oregovomab</title><link>https://mp.weixin.qq.com/s/hQ4JeYjIW7OKNI-_f_9lZA</link><description></description><content:encoded><![CDATA[海普瑞申报卵巢癌抗体疫苗Oregovomab]]></content:encoded><pubDate>Fri, 23 Apr 2021 12:18:33 +0800</pubDate></item><item><title>宜明昂科申报HER2/CD47双抗</title><link>https://mp.weixin.qq.com/s/8s2sbqMWbVAnoK5koLH-YA</link><description></description><content:encoded><![CDATA[宜明昂科申报HER2/CD47双抗]]></content:encoded><pubDate>Fri, 23 Apr 2021 12:18:33 +0800</pubDate></item><item><title>复旦张江申报Trop2 ADC，国内第5家</title><link>https://mp.weixin.qq.com/s/aj0MMBmuM6uVZdUv_G0acA</link><description></description><content:encoded><![CDATA[复旦张江申报Trop2 ADC，国内第5家]]></content:encoded><pubDate>Thu, 22 Apr 2021 06:48:33 +0800</pubDate></item><item><title>ADCC：抗体药体外免疫活性质检标杆</title><link>https://mp.weixin.qq.com/s/NavCyCmrOl6NroFFiBeL_A</link><description></description><content:encoded><![CDATA[ADCC：抗体药体外免疫活性质检标杆]]></content:encoded><pubDate>Thu, 22 Apr 2021 06:48:33 +0800</pubDate></item><item><title>非小细胞肺癌靶向治疗新时代</title><link>https://mp.weixin.qq.com/s/eOQN5wX6EJwirdrKxBagnA</link><description></description><content:encoded><![CDATA[非小细胞肺癌靶向治疗新时代]]></content:encoded><pubDate>Wed, 21 Apr 2021 11:09:37 +0800</pubDate></item></channel></rss>